11.57

0.70% 0.08

After Hours: 12.09 0.52 +4.49%

Atrium Therapeutics Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Atrium Therapeutics Inc stock is traded at $11.57, with a volume of 82,813. It is up +0.70% in the last 24 hours and down -12.28% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Previous Close:

$11.49

Open:

$11.61

24h Volume:

82,813

Relative Volume:

0.39

Market Cap:

$197.91M

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-3.0585

EPS:

-3.7829

Net Cash Flow:

$-502.70M

1W Performance:

-1.62%

1M Performance:

-12.28%

6M Performance:

-84.07%

1Y Performance:

-68.10%

1-Day Range:

$11.46

$11.80

1-Week Range:

$11.46

$12.35

52-Week Range:

$11.40

$73.06

Atrium Therapeutics Inc Stock (RNA) Company Profile

Name

Atrium Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

858-401-7900

Address

3020 CALLAN ROAD, SAN DIEGO, CA

Employee

391

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Atrium Therapeutics Inc	11.57	196.54M	10.73M	-455.74M	-502.70M	-3.7829
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Initiated	Wells Fargo	Overweight
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Atrium Therapeutics Inc Stock (RNA) Latest News

Jul 27, 2026

BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan

Jul 27, 2026

Jul 25, 2026

Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - TradingView

Jul 25, 2026

Jul 20, 2026

Atrium Therapeutics’ new hire receives options and 3,500 stock units - Stock Titan

Jul 20, 2026

Jul 17, 2026

Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et

Jul 17, 2026

Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail

Jul 17, 2026

Jul 16, 2026